Psychological Activity Study and In vitro Interaction of Azithromycin with Empagliflozin and Investigation of Antimicrobial Activity
Abstract
Azithromycin is used to treat or prevent certain bacterial infections, most often those causing middle ear infections, strep throat, pneumonia, typhoid, bronchitis, and sinusitis. In recent years, it has been used primarily to prevent bacterial infections in infants and those with weaker immune systems. Azithromycin and Empagliflozin commonly prescribed medications for the treatment of various medical conditions, including bacterial infections and type 2 diabetes, respectively. It should be mentioned that Azithromycin and Empagliflozin have no significant Psychological activity. The co-administration of these drugs is not uncommon, particularly in patients with comorbidities. However, concerns regarding potential drug interactions and their impact on safety and efficacy have arisen in clinical practice. This research paper explores the interaction between Azithromycin and Empagliflozin. An in-depth analysis was conducted through in-vitro studies. The primary objectives were to assess whether Empagliflozin has the potential to influence the pharmacokinetics of Azithromycin. The results revealed that Azithromycin can indeed interact with Empagliflozin. These findings suggest that the concurrent use of Azithromycin and Empagliflozin may necessitate dose adjustments or close monitoring to maintain therapeutic efficacy. Understanding the interaction between Azithromycin and Empagliflozin is crucial for optimizing patient care and ensuring the safe and effective management of…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.